Cite
HARVARD Citation
O'Byrne, K. et al. (n.d.). 69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7. Lung cancer. pp. S25-. [Online].